Literature DB >> 19382529

M. avium binding to HLA-DR expressed alleles in silico: a model of phenotypic susceptibility to sarcoidosis.

C Saltini1, M Pallante, E Puxeddu, S Contini, C E Voorter, M Drent, M Amicosante.   

Abstract

Sarcoidosis is a systemic granulomatosis disease of unknown origin where a number of microbes, in particular M. tuberculosis and non-tuberculous mycobacteria, have been hypothesized to play a role in disease pathogenesis, possibly through bacterial antigen-driven hypersensitivity. To test this concept, we used bioinformatic tools allowing the identification of antigenic peptides in whole microbial genomes to analyze the interaction between the expressed HLA-DR gene allelic variants and the HLA-DR immunome of all pathogenic bacteria in a population of 149 sarcoidosis affected subjects and 447 controls, all HLA-typed at high resolution. We show here that patients with the Löfgren's syndrome, express HLA-DR alleles that recognize in silico a significantly higher number of bacterial antigen epitopes compared to the control population (18,496+9,114 vs 17,954+8,742; p<0.00001), and the chronic sarcoidosis affected population (17,954+8,742; p<0.00001 vs Löfgren's and controls). Further, the analysis of the ability of the HLA-DR allele combinations expressed by the Löfgren's and the chronic sarcoidosis affected subjects to recognize M. avium epitopes demonstrates that a significantly larger number of Löfgren's are capable of top affinity recognition, compared to chronic sarcoidosis (45% vs 17%, p<0.0037). Finally, both Löfgren's and chronic sarcoidosis subjects expressed HLA-DR allele combinations capable of M. tuberculosis and M. avium epitope recognition at higher affinity than tuberculosis affected subjects (p<0.01 all comparisons). In conclusion, we propose that - at least in a subgroup of affected subjects - sarcoidosis might be part of a spectrum of granulomatous responses to several agents where the Löfgren's syndrome represents the hyper-reactive end of the spectrum while pulmonary tuberculosis and atypical mycobacterial infections might represent the opposite end.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19382529

Source DB:  PubMed          Journal:  Sarcoidosis Vasc Diffuse Lung Dis        ISSN: 1124-0490            Impact factor:   0.670


  7 in total

Review 1.  Sarcoidosis--scientific progress and clinical challenges.

Authors:  Edward S Chen; David R Moller
Journal:  Nat Rev Rheumatol       Date:  2011-07-12       Impact factor: 20.543

2.  Development of a sarcoidosis murine lung granuloma model using Mycobacterium superoxide dismutase A peptide.

Authors:  Carmen M Swaisgood; Kyra Oswald-Richter; Stephen D Moeller; Jennifer M Klemenc; Lisa M Ruple; Carol F Farver; John M Drake; Daniel A Culver; Wonder P Drake
Journal:  Am J Respir Cell Mol Biol       Date:  2010-03-26       Impact factor: 6.914

3.  Different HLA-DRB1 allele distributions in distinct clinical subgroups of sarcoidosis patients.

Authors:  Johan Grunewald; Boel Brynedal; Pernilla Darlington; Magnus Nisell; Kerstin Cederlund; Jan Hillert; Anders Eklund
Journal:  Respir Res       Date:  2010-02-26

Review 4.  Granuloma genes in sarcoidosis: what is new?

Authors:  Annegret Fischer; Benjamin A Rybicki
Journal:  Curr Opin Pulm Med       Date:  2015-09       Impact factor: 3.155

5.  Association of HLA-DRB1 with Sarcoidosis Susceptibility and Progression in African Americans.

Authors:  Albert M Levin; Indra Adrianto; Indrani Datta; Michael C Iannuzzi; Sheri Trudeau; Jia Li; Wonder P Drake; Courtney G Montgomery; Benjamin A Rybicki
Journal:  Am J Respir Cell Mol Biol       Date:  2015-08       Impact factor: 6.914

Review 6.  Etiologies of Sarcoidosis.

Authors:  Edward S Chen; David R Moller
Journal:  Clin Rev Allergy Immunol       Date:  2015-08       Impact factor: 8.667

Review 7.  Causal inference regarding infectious aetiology of chronic conditions: a systematic review.

Authors:  Sofia Orrskog; Emma Medin; Svetla Tsolova; Jan C Semenza
Journal:  PLoS One       Date:  2013-07-25       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.